Wednesday, August 14, 2019

MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) to Host Teleconference to Discuss Q2 2019 Financial Results and Provide Business Update


Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, on Tuesday announced that it will host a teleconference to discuss its second quarter 2019 financial results and to provide a business update. The teleconference is scheduled for 4:30 PM ET on Thursday, August 15, 2019, and will include a company presentation followed by a question and answer period. Interested parties may listen to the teleconference live by dialing (844) 602-0380 (North America); (862) 298-0970 (International) and entering the following verbal passcode for the operator: PBI Second Quarter 2019 Financial Call and Business Update. For those unable to participate in the live teleconference, a replay will be available beginning Friday, August 16, 2019, and will be accessible via telephone and the company’s website for 30 days. Interested parties may listen to the replay by dialing (877) 481-4010 (North America); (919) 882-2331 (International) and entering replay passcode: 53312.

To view the full press release, visit http://ibn.fm/7IZxr

About Pressure BioSciences Inc.

Pressure BioSciences (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life-sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented-enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of the company’s pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold Inc. to allow entry into the biologics-contract, research-services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and (ii) prepare higher-quality, homogenized, extended shelf-life or room-temperature stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html